These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 38962481)

  • 1. The effectiveness and predictors influencing the outcome of onabotulinumtoxinA treatment in chronic migraine: understanding from diverse patient profiles in a single session.
    Ilgaz Aydinlar E; Erdogan Soyukibar T; Yalinay Dikmen P
    Front Neurol; 2024; 15():1417303. PubMed ID: 38962481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of galcanezumab on sleep quality, migraine outcome, and multidimensional patient-reported outcome measures: a real-world experience in Turkish patients with episodic and chronic migraine.
    Ilgaz Aydinlar E; Erdogan Soyukibar T; Yalinay Dikmen P
    Front Neurol; 2024; 15():1411238. PubMed ID: 38887386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
    Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety.
    Boudreau GP; Grosberg BM; McAllister PJ; Lipton RB; Buse DC
    Int J Gen Med; 2015; 8():79-86. PubMed ID: 25733924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review.
    Blumenfeld AM; Frishberg BM; Schim JD; Iannone A; Schneider G; Yedigarova L; Manack Adams A
    Pain Ther; 2021 Dec; 10(2):809-826. PubMed ID: 33880725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study.
    Barbanti P; Egeo G; Aurilia C; Torelli P; Finocchi C; d'Onofrio F; d'Onofrio L; Rao R; Messina S; Di Clemente L; Ranieri A; Autunno M; Sette G; Colombo B; Carnevale A; Aguggia M; Tasillo M; Zoroddu F; Frediani F; Filippi M; Tomino C; Proietti S; Bonassi S;
    J Headache Pain; 2023 Mar; 24(1):30. PubMed ID: 36949388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.
    Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
    J Headache Pain; 2019 Jan; 20(1):10. PubMed ID: 30669961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
    Blumenfeld AM; Patel AT; Turner IM; Mullin KB; Manack Adams A; Rothrock JF
    J Prim Care Community Health; 2020; 11():2150132720959936. PubMed ID: 32985341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
    De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
    J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative and Qualitative Pain Evaluation in Response to OnabotulinumtoxinA for Chronic Migraine: An Observational Real-Life Study.
    Altamura C; Brunelli N; Viticchi G; Salvemini S; Cecchi G; Marcosano M; Fofi L; Silvestrini M; Vernieri F
    Toxins (Basel); 2023 Apr; 15(4):. PubMed ID: 37104222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
    Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
    J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.
    Mathew NT; Jaffri SF
    Headache; 2009; 49(10):1466-78. PubMed ID: 19912346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis.
    Armanious M; Khalil N; Lu Y; Jimenez-Sanders R
    J Pain Palliat Care Pharmacother; 2021 Mar; 35(1):1-6. PubMed ID: 33125303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
    Aurora SK; Dodick DW; Diener HC; DeGryse RE; Turkel CC; Lipton RB; Silberstein SD
    Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
    Stark C; Stark R; Limberg N; Rodrigues J; Cordato D; Schwartz R; Jukic R
    J Headache Pain; 2019 Jul; 20(1):81. PubMed ID: 31307383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review.
    Blumenfeld AM; Mechtler L; Cook L; Rhyne C; Jenkins B; Hughes O; Dabruzzo B; Manack Adams A; Diamond M
    Pain Ther; 2024 Dec; 13(6):1571-1587. PubMed ID: 39287781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraine.
    Mahon R; Vo P; Pannagl K; Tiwari S; Heemstra H; Ferraris M; Zhao J; Betts KA; Proot P
    Curr Med Res Opin; 2023 Jan; 39(1):105-112. PubMed ID: 36189948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
    Ahmed F; Gaul C; García-Moncó JC; Sommer K; Martelletti P;
    J Headache Pain; 2019 Mar; 20(1):26. PubMed ID: 30845917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
    Barbanti P; Egeo G; Aurilia C; d'Onofrio F; Albanese M; Cetta I; Di Fiore P; Zucco M; Filippi M; Bono F; Altamura C; Proietti S; Bonassi S; Vernieri F;
    J Headache Pain; 2022 Apr; 23(1):46. PubMed ID: 35397503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.